Navigation Links
Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound
Date:10/1/2008

Pivotal Study to Provide Real-World Dosing Simulation of Lilly's

Gamma-Secretase Inhibitor

INDIANAPOLIS, Oct. 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced it will begin enrolling patients in a second Phase III study of LY450139, a gamma-secretase inhibitor being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease. The study, called IDENTITY 2, is expected to enroll 1,100 patients from 22 countries. When its results are evaluated along with findings from the first Phase III trial, IDENTITY, a more complete understanding of dosing strategies will be available from a truly global sample of patient data. Because of the study design, IDENTITY 2 will give additional insights into how LY450139 might be dosed in a real-world clinical setting. Patients or caregivers interested in learning more about how to enroll in either IDENTITY study are encouraged to visit http://www.lillytrials.com or call 1-877-CTLilly (1-877-285-4559).

While the precise cause of Alzheimer's disease is not known, current theory is that subtypes of amyloid beta, a type of sticky protein, clump together and eventually kill brain cells, causing the symptoms of the disease. LY450139 is a once-daily oral agent that is believed to slow the progression of Alzheimer's disease by inhibiting gamma secretase, an enzyme that can create amyloid beta. By blocking gamma secretase, there is less amyloid beta formed and potentially less brain cell death.

"We are proud to begin a second global trial of our gamma-secretase inhibitor in patients suffering from the devastating effects of Alzheimer's disease,"
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Calif. , May 5, 2015 ... biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic ... clinical trial evaluating tenapanor in Stage 3 chronic ... and albuminuria did not meet the primary endpoint ... patients compared to patients receiving placebo. ...
(Date:5/5/2015)... , May 5, 2015 North ... $94.9 million in 2014, and is estimated to grow ... 7.8% from 2014 to 2019. Browse through ... Market for an analysis of industry trends and segments, ... http://www.micromarketmonitor.com/market/north-america-glaucoma-surgery-devices-8830146604.html Early buyers ...
(Date:5/5/2015)... Valley Medical Center, named a Top 100 Hospitals® in the ... to deploy the wireless Leaf Patient Monitoring System in its ... labor and risk of caesarian births. Studies show ... is reduced in mothers who are upright and mobile during ... epidurals and tend to lie in their labor room beds. ...
Breaking Medicine Technology:Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 2North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 2Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 4
... , RYE, N.Y. , July 28 Curemark, ... on the treatment of neurological diseases, announced that Saint Peter,s University Hospital ... Phase III clinical trials for CM-AT , Curemark,s autism treatment.   ... Saint Peter,s is affiliated ...
... SEATTLE , July 28 HemaQuest Pharmaceuticals, ... for sickle cell disease, beta thalassemia and EBV-related cancers, ... to its Series B financing by new investor, ... B financing to $16M . The financing is ...
Cached Medicine Technology:Curemark Opens Autism Trials at New Jersey Site 2Curemark Opens Autism Trials at New Jersey Site 3HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing 2
(Date:5/5/2015)... May 05, 2015 Leveraging the industry-leading ... in Greece, an experienced team of fertility specialists are ... for patients around the globe. , “We’re honored that ... unquestionably remains a global leader in reproductive medicine. The ... fertility specialists in the world who play an important ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 From ... the established leader in enabling enterprise collaboration ... to help customers speed up and simplify the ... technologies, AvePoint Solutions for Office 365 ... faster while ensuring sustainable user adoption and effectively ...
(Date:5/5/2015)... Patricia George knows all too well the debilitating effects ... specialist at the University of Pittsburgh Medical Center (UPMC), ... idea entered her mind for Team PHenomenal Hope. ... 2010 PHA International Conference,” George recalled. “The speakers – ... climb up Mt. Kilimanjaro and I remember thinking how ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 This year, ... Medals, four Special Merit Awards, three Gold Medals and ... projects are described as follows: , (1) Grand Prize ... Robotic Mannequin for Fashion Design and Fitting, Principal Investigator: ... , The apparel industry relies very much on the ...
(Date:5/5/2015)... Freeport, Grand Bahama (PRWEB) May 05, 2015 ... published its Orthopedic Lifestyle Report today. The study was ... orthopedic conditions such as osteoarthritis and sports-related ... chronic pain and stiffness was the most prevalent symptom ... reduced functionality such as walking, standing and bending over. ...
Breaking Medicine News(10 mins):Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 3Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 3Health News:World PH Day: Team PHenomenal Hope Races to Spread the Word about Pulmonary Hypertension 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 2Health News:PolyU wins top prizes in Geneva’s Invention Expo 3Health News:PolyU wins top prizes in Geneva’s Invention Expo 4Health News:PolyU wins top prizes in Geneva’s Invention Expo 5Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3
... from the ceremony long used to initiate Jewish boys ... parents decided to move away from the tradition of ... the foreskin from the penis. ,There was no crying, ... traditionally performs ritual circumcisions in the Jewish faith.,``I knew before ...
... discovered an association between foie gras prepared from goose ... in rheumatoid arthritis or tuberculosis. ,Dr. Alan Solomon, ... School of Medicine in Knoxville, says that the new ... that a food product can hasten amyloid development. ...
... A 111-year-old Japanese engineer born at the end of the ... world's newest oldest man, and joked he was sorry for ... said that avoiding alcohol was a secret of his ... World Records by the mayor of his local municipality. ...
... a ban on the use of plastic and polythene materials ... day before flooded Guwahati, throwing the city out of ... ban the use of plastic and polythene is one of ... would be enforced very strictly and there would be penalties ...
... a scientific study has backed them up by showing that ... than they really are. Researchers at the University of Alberta ... of Victoria, carried out the study. ,As a ... nearly 700 adolescents between 12 to 19 years of age ...
... who recently starred in 'Ocean's 13' did not scold ... of marijuana because she used to smoke it ... to ignore the incident even though she knew he ... ,She says: 'I used to smoke with my ...
Cached Medicine News:Health News:The Custom of Circumcision Decline in the US 2Health News:Scientists Establish Link Between Foie Gras and Disease 2Health News:Dating, Drugs and Sex Make Teens Feel Older Than They are 2
... The Techne TC-312 Thermal Cycler is ... market. Features & Benefits include: ... networking, Alpha-numeric screen, keypad and program naming, ... numerous applications in Molecular Biology and Diagnostic ...
PTC-100 cycler with Hot Bonnet heated lid,holds sixty 0.5ml tubes...
... 0.2ml sub-ambient block and automatic height adjusting ... up to 3C/second; Accurate block performance; Absolute ... than 0.5C within 15 seconds; Oil free ... storage of up to 60 programs; 0.2 ...
... The RapidCycler is the first instrument ... reactions. The instrument's rapid temperature cycling system ... air to samples contained in microcapillary tubes ... cooling the samples with blasts of high ...
Medicine Products: